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Abstract 
The Hodgkin/Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (HL) are characterised 
by the aberrant activation of multiple signalling pathways. Here we show that a subset of HL 
displays altered expression of sphingosine-1-phosphate (S1P) receptors (S1PR). S1P activates 
phosphatidylinositide 3-kinase (PI3-K) in these cells that is mediated by the increased expression 
of S1PR1 and the decreased expression of S1PR2. We also showed that genes regulated by PI3-K 
signalling pathway in HL cell lines significantly overlap with the transcriptional programme of 
primary HRS cells. Genes up-regulated by the PI3-K pathway included the basic leucine zipper 
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transcription factor, ATF-like 3 (BATF3), which is normally associated with the development of 
dendritic cells. Immunohistochemistry confirmed that BATF3 was expressed in HRS cells of most 
HL cases. In contrast, in normal lymphoid tissues, BATF3 expression was confined to a small 
fraction of CD30-positive immunoblasts. Knockdown of BATF3 in HL cell lines revealed that 
BATF3 contributed to the transcriptional programme of primary HRS cells, including the up- 
regulation of S1PR1. Our data suggest that disruption of this potentially oncogenic feed-forward 
S1P signalling loop could provide novel therapeutic opportunities for patients with HL. 
 
 
Introduction 
 
S1P is a bioactive sphingolipid metabolite implicated in cancer growth, survival and 
invasion.1,2 S1P is generated by the enzyme, sphingosine kinase 1 (SPHK1), which is over- 
expressed in different cancer types, including some non-HL.3 Conversely, sphingosine-1- 
phosphate phosphatase (SGPP1), which degrades S1P, is down-regulated during tumour 
development and progression.4±6 Although the over-production of S1P is a characteristic of 
many cancers, the biological responses to S1P are governed by binding and activation of 
five cell surface S1P receptors (S1PR1-5); each coupling to a different repertoire of G 
proteins. In B cells, S1PR1 mediates mitogenic/pro-survival and chemotactic S1P functions 
by coupling to Gi to activate Ras/ERK, PI3-K/Akt and Rac,7±9 whereas S1PR2 couples to 
G12/13 to inhibit PI3-K/Akt activity leading to reduced cell growth, survival and migration. 
10±14 S1PR1 has previously been reported to be over-expressed in HRS cells and to 
promote their migration in vitro.15 In contrast, S1PR2 may be a tumour suppressor in B cell 
lymphomas; previous studies show that S1PR2 is mutated in a subset of human diffuse large 
B-cell lymphoma (DLBCL) and that mice lacking S1PR2 expression develop DLBCL.16,17 
 
Here we show that HRS cells are characterised by high expression of SPHK1 and S1PR1, 
but do not express S1PR2. This leads to enhanced PI3-K activation in response to S1P and 
to the increased expression of the dendritic cell transcription factor (TF), BATF3 (ref. 
18,19). In turn, BATF3 contributes to the transcriptional programme of HL, including the 
increased expression of S1PR1. Interrupting this BATF3-regulated feed-forward loop, for 
example by targeting S1PR1, could provide novel therapies for HL patients. 
 
Materials and Methods 
 
Cells and tissues 
Paediatric tonsils and tumour samples were obtained with informed consent under local 
ethics committee approval (06/Q2702/50; REC_RG_HBRC_12-071). Germinal center (GC) 
B cells were isolated and characterised as described earlier.20±22 Isolation of blood-derived 
B cells and preparation of lymphoblastoid cell lines (LCL) were described before21±23 and 
are detailed in SI Materials and Methods (M&M). KMH2, L428, L1236 and L540 are 
Epstein Barr virus (EBV)-negative HL cell lines and L591 is an EBV-positive HL cell line. 
DG75 is an EBV-negative Burkitt lymphoma cell line. HEK293 is derived from human 
embryonic kidney. Cell lines were cultured at 37°C in 5% CO2 in either RPMI1640 or 
DMEM (HEK293) with 10% foetal calf serum (FCS) and 1% penicillin-streptomycin (all 
ThermoFisher Scientific, Waltham, MA, USA). 
 
 
 
Leukemia. Author manuscript. 
©    2017 Macmillan Publishers Limited. All rights reserved.
Europe
 PM
C
 F
u
nders A
uthor M
an
u
scripts
 
Europe
 PM
C
 F
u
nders A
uthor M
an
u
scripts
 
Vrzalikova et al. Page 3 
 
S1P measurements 
 
For measurement of S1P levels in cell lines and B cells, lipids were extracted and 
sphingolipids quantified by liquid chromatography-electrospray ionization-tandem mass 
spectrometry (LC-ESI-MS/MS; 4000 QTRAP, AB Sciex, Framingham, MA, USA) as 
previously described.24 
 
Treatment of cells 
 
Preparation of S1P (Sigma-Aldrich, St. Louis, MI, USA) is detailed in SI M&M. For S1P 
treatment, KMH2 cells were washed twice, incubated in serum-free media for 1h, followed 
by addition of 1µM S1P. S1P receptor functional antagonists, Ozanimod (RPC1063, 
Selleckchem.com, Munich, Germany) or Siponimod (BAF312, Selleckchem.com), were 
added to cells 1h prior to 15min S1P stimulation. For measurement of viability, cells were 
stained using FITC Annexin V ASRSWRVLV'HWHFWLRQ.LW,%'3KDUPLQJHQ)UDQNOLQ
Lakes, NJ, USA) and analysed by flow cytometry. For Akt inhibition, cells were cultivated 
in 10% FCS media with 1µM Ipatasertib (GDC-0068; Selleckchem.com) or vehicle 
(DMSO) for 6h. Cell-Titer Glo assay (Promega, Fitchburg, WI, USA) showed no cell death 
at this time point. 
 
For PI3-K inhibition, cells were cultivated in 10% FCS media with 30µM LY294002 or 
vehicle (DMSO). We have previously shown that LY294002 does not cause significant cell 
death at the time points and concentration used.25 
 
Gene expression in KMH2 cells following 16h of LY294002/vehicle treatment was analysed 
with Affymetrix HG-Focus arrays (data available from GSE89759). The data was 
background subtracted and quantile normalized26,27 using the affy package of 
Bioconductor. Differentially expressed genes were identified using limma28 (p<0.05, 
absolute fold change >1.2). Probe sets with "Negative Strand Matching Probes" were 
removed from the significant gene list. Gene ontology analysis was performed using DAVID 
6.7 http://david.abcc.ncifcrf.gov using GO-term BP-FAT; p<0.01, >=1.3-fold enrichment. 
 
BATF3 knockdown 
 
BATF3 knockdown was performed by nucleofection with Silencer® Select s195280 BATF3 
siRNA or Silencer® Select Negative Control No.1 siRNA (ThermoFisher Scientific). 48h 
after BATF3 knockdown in L428 cells, samples were hybridized to Affymetrix PrimeView 
arrays (data available from GSE89760) and data analysed as described above. 
 
Re-analysis of publicly available datasets is described in SI M&M. Chi-squared test was 
used to identify significant enrichment or depletion of either PI3-K or BATF3 target genes in 
these datasets using a threshold for significance of p<0.05. 
 
Transfection of cells 
GC B cells were nucleofected with pcDNA3.1-PRDM1 or empty vector, cultivated and 
enriched as before.20,21 HL cell lines and DG75 cells were transfected by nucleofection 
(Lonza, Basel, Switzerland) and HEK293 transfected by lipofectamine (ThermoFisher 
Scientific) using the following vectors and corresponding controls: pcDNA3.1-S1PR2-HA 
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(UMR cDNA Resource Center University of Missouri-Rolla, MO, USA), pSG5-myc-p1Į- 
&$$;-XOLDQ'RZQZDUG$GGJHQH&DPEULGJH0$86$$NW3.%ĮF'1$DFWLYDWHG
in pUSEamp containing a MYC tag (Merck Millipore, Billerica, MA, USA), pcDNA3.1- 
S1PR1 (Dr Ian Paterson, University of Malaya) and pCMV6-SPHK1 (Origene technologies, 
Rockville, MD, USA). 
 
Quantitative RT- PCR (Q-PCR) 
RNA was extracted with RNeasy Mini/Micro Kit including genomic DNA removal with 
RNase-Free DNase Set (QIAGEN, Hilden, Germany). cDNA was JHQHUDWHGZLWKT6FULSW
cDNA SuperMix (VWR International, Radnor, PA, USA). Gene transcripts were quantified 
with commercial assays (Table S1A, ThermoFisher Scientific) as before.21 The 2íǻ&W
method was used to quantify target expression relative to GAPDH housekeeping control 
(unless specified otherwise). 
 
Immunoblotting 
 
Immunoblotting was performed with the primary antibodies detailed in Table S1B and 
following standard techniques described in SI M&M. 
 
Immunohistochemistry (IHC) 
 
IHC was performed as before.29,30 Slides were blocked in 5x casein followed by primary 
antibody in 0.05% PBS/Tween (Table S1C). Multiplex immunofluorescence (IF) was 
SHUIRUPHGXVLQJ2SDO-Plex Kit (NEL791001KT; PerkinElmer, Waltham, MA, USA). 
For antibody stripping between each step, slides were microwaved in pH=6 citrate buffer, 
with controls omitting individual antibody steps to ensure adequate stripping. Slides were 
scanned using wide-range wavelength covering filters available in Vectra system 3.0.3 (For 
dyes-Cyanine 5, Cyanine 3, DAPI, Texas Red, Fluorescein). Antibodies were optimized with 
auto-exposure adjustment (100-150ms). Images were taken on Olympus BX-51WI 
microscope with 10x, 20x and 40x magnification. Multispectral images were analysed using 
InForm Automated Image Analysis software version 2.2.1 for phenotyping and 
quantification of co-expressed markers. Analysis was performed with a 20x objective on a 
minimum of three fields for cytospin preparations and five fields for tissue sections. For 
assessment of protein expression following S1P treatment the mean intensity and SD were 
calculated for each of three fields separately and statistical significance measured by Fisher 
exact test. For image analysis of TMA we used the 1x1 function covering approximately 
75% of each core. Positivity in IHC was assessed with 40x objective using the whole TMA 
area, or ten representative hpf in the case of whole sections. To directly compare our results 
with those previously reported by Kluk et al,15 S1PR1 was scored as positive if >=25% of 
cells expressed S1PR1. The same cut-off was applied for all other markers. Validation of the 
specificity of SPHK1, S1PR1, S1PR2 and BATF3 antibodies is shown in Figure S1. 
 
Results 
 
Expression of SPHK1, SGPP1 and S1P receptors in HRS cells 
 
We first studied the expression of SPHK1 and SGPP1, enzymes important for regulating 
S1P levels.3±5 We showed that SPHK1 was expressed in both normal GC B cells and in 
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HRS cells in most cases (49/58; Figure 1A; Table S2). Owing to the lack of an internal 
positive control we could not reliably quantify SPHK1 expression by IHC. Therefore, we re- 
analysed a microarray dataset that compared global gene expression in B cell lymphomas 
with that in normal B cell subsets.31 This revealed significantly higher SPHK1 mRNA in 
micro-dissected HRS cells compared with isolated GC B cells (Figure S2A). Re-analysis of 
a second independent microarray dataset32 revealed higher expression of SPHK1 mRNA in 
both EBV-negative and EBV-positive HRS cells compared to micro-dissected GCs (Figure 
S2B). Q-PCR showed that SPHK1 mRNA expression was also higher in HL cell lines than 
in GC B cells (Figure 1B). We next used immunoblotting to show that SPHK1 was 
constitutively activated in HL cell lines (Figure 1C). Conversely, SGPP1 mRNA was 
decreased in primary HRS cells and HL cell lines compared with normal GC B cells (Figure 
S3). Indeed, S1P levels measured by mass spectrometry were higher in HL cells than in 
normal B cells (Figure 1D). We next studied the expression of S1PR1 and S1PR2. We 
showed that normal GC B cells expressed S1PR2, but not S1PR1 (Figure 2A, S4). In 
comparison, HRS cells frequently expressed S1PR1 (36/61), but not S1PR2 (2/61), an 
observation we confirmed by multiplex staining with CD30 (Figure 2B, S5; Table S2). We 
conclude that in contrast to their normal counterparts, HRS cells appear to express high 
levels of SPHK1 and S1PR1 but lack expression of S1PR2 and SGPP1. 
 
S1P-induced PI3-K signalling in HRS cells is mediated by the differential expression of 
S1P receptors 
 
We next studied the effects of S1P on PI3-K signalling in HRS cells using Akt 
phosphorylation as a read-out. We chose the KMH2 cell line for these experiments because 
it expresses S1PR1 and only low levels of S1PR2 in the absence of the other S1P receptors 
(Figure S6A,B). We observed that the addition of S1P increased Akt phosphorylation in 
KMH2 cells (Figure 3A). To examine the effect of S1PR1 on Akt phosphorylation, we 
stimulated KMH2 cells with S1P after targeting S1PR1 (and S1PR5) with their functional 
antagonists Ozanimod and Siponimod.33,34 The addition of either drug 1h prior to S1P 
treatment decreased Akt phosphorylation in a dose-dependent manner (Figure 3B). 
Furthermore, Ozanimod significantly reduced the viability of KMH2, L428 and L591 cells 
while Siponimod reduced the viability of KMH2 and L428 cells (Figure S7). L1236 was 
resistant to both drugs. To study the effect of S1PR2, we transfected KMH2 cells with an 
S1PR2-HA expression vector and used IF to detect phospho-Akt and the HA tag. Cells 
ectopically expressing S1PR2 were significantly more likely to be phospho-Akt negative 
than HA-negative cells in the same transfected population, an effect we observed with 
(p<0.0001; Figure S8) and without (p<0.0001; not shown) the addition of exogenous S1P. 
Taken together, our data suggests that binding of S1P to S1PR1 can activate PI3-K 
signalling in HRS cells. 
 
Expression of the transcription factor, BATF3, is regulated by PI3-K signalling in HRS cells 
To identify the transcriptional targets of PI3-K signalling pathway in HL cells, we used the 
pan-PI3-K inhibitor LY294002. KMH2 cells were treated with LY294002 for 16h under 
conditions that do not affect viability.25 The addition of LY294002 for 16h was followed by 
the up-regulation of 694 genes and the down-regulation of 330 genes (Table S3). We 
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validated a number of PI3-K targets genes in KMH2, and also in L428, L591 and L1236 
cells (Figure S9). 
 
Re-analysis of GSE12453 (Brune et al31) identified 743 genes up-regulated and 622 genes 
down-regulated in micro-dissected HRS cells compared with normal centrocytes (Table S4). 
Genes up-regulated in HRS cells (OR=2.15; p<0.0001), but not those down-regulated in 
HRS cells (OR=1.00; p=0.96), were significantly enriched in genes down-regulated 
following PI3-K inhibition. Similarly, genes down-regulated in HRS cells (OR=2.95; 
p<0.0001), but not those up-regulated in HRS cells (OR=1.28; p=0.056), were significantly 
enriched in genes up-regulated following PI3-K inhibition (Figure S10; Table S5). These 
data indicate that the activation of PI3-K signalling pathway contributes to the 
transcriptional programme of HRS cells. We next wanted to establish if this was also the 
case for both the EBV-positive and EBV-negative forms of HL. To do this we re-analyzed 
data from the second published microarray which had compared gene expression in micro- 
dissected HRS cells with that in micro-dissected normal GCs and which had reported EBV 
status for a subset of cases GSE39133 (Steidl et al32). The transcriptional targets of PI3-K 
signalling we had identified in primary HRS cells were significantly enriched in those genes 
differentially expressed in both EBV-positive and EBV-negative HRS cells (Figure S10; 
Tables S6-S9). 
 
A gene ontology (GO) analysis revealed that genes regulated by PI3-K signaling pathway in 
SULPDU\+56FHOOVZHUHHQULFKHGIRUWKRVHZLWKDIXQFWLRQLQµWUDQVFULSWLRQLQLWLDWLRQIURP
RNA polymerase II promoter¶VXJJHVWLQJWKDW3,-K signalling might contribute to the 
aberrant expression of TFs observed in HRS cells (Figure 4A). To identify relevant TFs 
targets we compared genes regulated by PI3-K signalling in primary HRS cells with a 
comprehensive set of TFs described by Vaquerizas et al.35 This revealed the up-regulation 
of 12, and the down-regulation of 47 TFs by PI3-K signalling in HRS cells (Figure 4B). 
They included the dendritic cell TF, BATF3 (ref. 18,19), which was previously reported to 
be over-expressed at the mRNA level in HRS cells36,37 and which was also the PI3-K 
regulated gene most highly up-regulated in the re-analysis of global gene expression in 
primary HRS cells described above.31,32 We confirmed that LY294002 down-regulated 
BATF3 expression in HL cell lines (Figure S11A,B). Furthermore, the pan-Akt inhibitor, 
Ipatasertib, also decreased BATF3 expression (Figure S11C). To confirm these were not off- 
target effects, we transfected KMH2 cells with a MYC-tagged plasmid containing a 
constitutively active p110 or Akt1 gene and performed IF, titrating the MYC antibody to 
detect only exogenous MYC. We found, that a larger proportion of cells ectopically 
expressing either p110 (Figure S11D) or Akt1 (not shown) were significantly more likely to 
be both phospho-Akt- and BATF3-positive (p<0.0001) than were un-transfected cells. Taken 
together, our data show that activation of PI3-K/Akt signalling pathway leads to aberrant 
BATF3 expression in B cell lymphoma. 
 
BATF3 overexpression contributes to the transcriptional programme of HRS cells 
We confirmed that BATF3 mRNA expression was higher in micro-dissected HRS cells 
compared with normal B cells (Figure S12A) and in both EBV-positive and EBV-negative 
HRS cells compared with micro-dissected GCs (Figure S12B). IHC of normal lymphoid 
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tissues revealed that BATF3 protein was not present in GC B cells and only rarely in 
extrafollicular CD20-positive cells which were also CD30-positive (Figure 5A). In contrast, 
BATF3 protein was strongly expressed in both EBV-positive (7/10) and EBV-negative 
(29/42) HRS cells (Table S10) confirmed by CD30 co-staining (Figure 5B), and in HL lines 
(Figure 5C,D). BATF3 expression was also increased after EBV infection of B cells (Figure 
S13). 
 
A microarray analysis following BATF3 knockdown in L428 cells revealed the up- 
regulation of 960 genes and the down-regulation of 1066 genes (Table S11A,B). Taking 
genes only present on the Primeview platform and also on GSE12453,31 we found that 
genes down-regulated by BATF3 were significantly enriched in genes down-regulated in 
primary HRS cells (OR=1.8; p<0.0001). A GO analysis of BATF3 target genes revealed the 
enrichment of a number of HL-related *2WHUPVZKLFKLQFOXGHGµO\PSKRF\WH
difIHUHQWLDWLRQ¶µVRPDWLFGLYHUVLILFDWLRQRILPPXQHUHFHSWRUV¶µUHJXODWLRQRIFHOOPRWLRQ¶ 
µSRVLWLYHUHJXODWLRQRIWUDQVFULSWLRQIURP51$SRO\PHUDVH,,SURPRWHr¶DQGµ%FHOO
PHGLDWHGLPPXQLW\¶)LJXUH$We validated several BATF3 targets within different 
functional groups including genes down-regulated (JUN, FOS, ATF3, EGR1, EGR2, 
PTPRC, CASP7, CASP14, RGS1, RGS16) and genes up-regulated (BACH2, STAT5B, 
CXCL16) by BATF3 (Figure S14). We noted that BATF3 decreased the expression of 
PRDM1, which encodes BLIMP1 (Figure S14), a TF down-regulated in HRS cells and 
which is essential for plasma cell differentiation.21,38±41 Interrogation of our previous 
microarray dataset21 which described the transcriptional changes that follow the expression 
of BLIMP1 in primary GC B cells, also revealed a reciprocal regulation of BATF3 by 
BLIMP1 (Figure S15A). We confirmed the down-regulation of BATF3 by BLIMP1 by Q- 
PCR analysis of a further three donors (Figure S15B). These data show that the over- 
expression of BATF3 contributes to the aberrant transcriptional programme of HRS cells, 
including the down-regulation of BLIMP1. 
 
BATF3 up-regulates S1PR1 expression 
 
The knockdown of BATF3 significantly decreased S1PR1 mRNA and protein levels in 
L428, L1236 and KMH2 cells (all p<0.0001; Figure 7A, S16). In control and BATF3- 
siRNA-treated cells (p<0.0001; Figure 7B) as well as in untreated cells (Table S12), BATF3 
and S1PR1 levels were also significantly correlated at the single cell level. Next, we wanted 
to show that this pathway was directly regulated by S1P. To do this we treated the HL cell 
lines with S1P or control (BSA) for 24h and measured the levels of phospho-Akt, BATF3 
and S1PR1 by IF. S1P significantly increased the levels of phospho-Akt, BATF3 and S1PR1 
in L428, KMH2 and L591 cells (Figure S17). This regulation could be observed at the single 
cell level because S1P-treated cells were significantly more likely to co-express phospho- 
Akt, BATF3 and S1PR1 (all p<0.0001; not shown). S1P did not increase the expression of 
phospho-Akt and BATF3 in L1236 cells; most likely owing to the very high constitutively 
activated Akt in these cells and in keeping with their resistance to S1PR1 inhbition 
described above. Finally, we measured BATF3 and S1PR1 expression in primary HRS cells. 
We found that BATF3-positive primary HL were significantly more likely to be S1PR1- 
positive than BATF3-negative HL (p=0.0006; Figure S18A, Table S10). Single cell image 
analysis of six representative HL cases showed that BATF3-positive HRS cells within each 
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case were also significantly more likely to be S1PR1-positive than were BATF3-negative 
cells (Figure S18B). Taken together our results suggest the existence of a feed-forward S1P 
signalling loop that drives constitutive BATF3 expression leading to aberrant transcription in 
HRS cells. 
 
Discussion 
 
Here we show that HRS cells express BATF3, a TF that is important for the development of 
&'ĮFODVVLFDOGHQGULWLFFHOOVDQGUHODWHGQRQ-lymphoid CD103+CD11b- dendritic cells. 
19 Re-analysis of existing global expression datasets and IHC showed that BATF3 
expression was significantly higher in primary HRS cells compared with normal B cells. 
Our data also revealed that BATF3 is regulated by PI3-K/Akt signalling, a pathway we and 
others have shown is constitutively activated in HRS cells.25,42,43 
 
We also showed that PI3-K/Akt signalling pathway is regulated by S1P in HRS cells and that 
this is dependent upon the increased expression of S1PR1 together with the decreased 
expression of S1PR2. The up-regulation of S1PR1 in HRS cells has been reported before15, 
albeit in only 7/57 cases, a lower proportion than we have reported here; despite the fact that 
we used the same cut-off employed by Kluk et al. Our observation that BATF3 induces the 
expression of S1PR1 identifies a feed-forward loop which leads to constitutive S1P 
signalling, activation of the PI3-K/Akt pathway and sustained BATF3 transcriptional activity 
(Figure 8). The major source of the S1P necessary to sustain this loop is likely to be the HRS 
cells, since they express SPHK1 in the absence of the S1P phosphatase, SGPP1. The feed- 
forward loop described here could be important for the pathogenesis of HL since it has been 
shown that the knockdown of BATF3 significantly reduces the survival of HL cell lines44 
and that BATF3 can induce B cell lymphomas in a murine model (Weiser et al, personal 
communication). 
 
Our studies revealed that BATF3 down-regulated expression of BLIMP1, a TF required for 
plasma cell differentiation and which is either mutated or transcriptionally down-regulated 
in B cell lymphomas, including HL.21,38±41 BLIMP1 also decreased the expression of 
BATF3, indicating a reciprocal regulation of BATF3 and BLIMP1. Furthermore, BATF3 
increased the expression of BACH2 which has been shown to delay BLIMP1 expression and 
plasma cell differentiation in mouse lymphocytes.45,46 These data suggest that the 
constitutive expression of BATF3 could be important for the suppression of terminal B cell 
differentiation in HRS cell progenitors. 
 
In keeping with the reported down-regulation of AP-1 signalling by BATF3 (ref. 47), we 
observed that BATF3 decreased the transcription of the key AP-1 components, JUN, FOS 
and ATF3. Furthermore, we showed that BATF3 regulated many other transcriptional 
changes characteristic of HRS cells. These included the down-regulation of PTPRC (CD45), 
an essential regulator of BCR signalling48,49 and a number of TFs, including STAT5B, 
NOTCH1 and EGR1, known to be aberrantly expressed in HRS cells.50±53 
 
In a re-analysis of the BATF3 targets reported by Lollies et al44 (using the same cut-off as 
in our array, but using shRNA and different time point), we found that genes up-regulated 
(OR=1.62; p=0.003), but not those down-regulated (OR=0.96; p=0.89) by BATF3 in our 
 
 
Leukemia. Author manuscript. 
©    2017 Macmillan Publishers Limited. All rights reserved.
Europe
 PM
C
 F
u
nders A
uthor M
an
u
scripts
 
Europe
 PM
C
 F
u
nders A
uthor M
an
u
scripts
 
Vrzalikova et al. Page 9 
 
array were significantly enriched in those genes up-regulated by BATF3 in Lollies et al. 
Similarly, genes down-regulated (OR=2.7; p<0.00001), but not those up-regulated 
(OR=0.82; p=0.37), by BATF3 in our array were significantly enriched in those genes down- 
regulated by BATF3 in Lollies et al. It is noteworthy that S1PR1 was among those genes 
significantly up-regulated by BATF3 in Lollies et al. 
 
Both EBV-positive and EBV-negative HRS cells expressed BATF3, consistent with our 
observation that BATF3 expression was increased by in vitro EBV infection. Because the 
EBV lytic cycle has been shown to be induced upon terminal B cell differentiation54 leading 
to viral replication and cell death, the increased BATF3 expression observed in EBV- 
infected tumor cells could be important for suppression of the lytic cycle, in turn preventing 
replication-induced cell death. In keeping with this, several of the BATF3 targets we 
identified (e.g. AP-1, EGR1, BLIMP1), are known to induce the EBV lytic cycle.21,55±59 
 
Our data also suggest that the therapeutic blockade of S1P signalling could inhibit the 
oncogenic effects of BATF3. The two functional antagonists of S1PR1, Ozanimod and 
Siponimod, which we showed can block the S1P-mediated activation of Akt, are already in 
phase II and III clinical trials of patients with inflammatory and autoimmune diseases. These 
and other S1PR1 modulators should be investigated for their therapeutic potential in HL. 
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Figure 1. Expression of SPHK1 in normal lymphoid tissues and HRS cells 
A) SPHK1 expression in GC B cells and primary HL. Black arrows show HRS cells. 
GC=germinal center, MZ=mantle zone B) SPHK1 mRNA and C) protein expression in HL 
cell lines. T1-4 are GC B cells isolated from 4 donors. Note, SPHK1 is phosphorylated in all 
HL cell lines. D) S1P levels in HL cell lines and B cells (mean of three different donors) 
measured by mass spectrometry. 
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Figure 2. Expression of S1PR1 and S1PR2 in normal lymphoid tissues and HRS cells 
A) Normal tonsil. Upper panels: S1PR1 expression in MZ B cells, but not in GC B cells, 
confirmed by co-staining for CD20. Lower panels: S1PR2 was expressed in normal GC B 
cells, confirmed by co-staining with CD20 (white arrow) and BCL6 (Figure S4). B) HRS 
cells expressed S1PR1 but not S1PR2 (white arrows) confirmed by CD30 co-staining. 
Endothelial cells and red blood cells were strongly positive for S1PR1 and S1PR2, 
respectively (black arrows). Further examples of S1PR1 staining in HRS cells indicating the 
presence of both membrane and cytoplasmic staining are shown in Figure S5. 
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Figure 3. S1P activates Akt in HRS cells mediated by differential expression of S1P receptors 
A) Immunoblot of KMH2 cells following S1P stimulation and B) following 1h pre- 
treatment with increasing concentrations of Ozanimod or Siponimod. 
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Figure 4. PI3-K signalling up-regulates BATF3 in HRS cells 
A) GO analysis of genes regulated by PI3-K signalling in primary HRS cells (GSE1245331 
or GSE3913332 data or both; total of 137 up-regulated and 443 down-regulated genes) 
revealed enrichment of several funcWLRQVLQFOXGLQJµWUDQVFULSWLRQLQLWLDWLRQIURP51$
polymerase II promoter¶%&RPSDULVRQRIJHQHVUHJXODWHGE\3,-K signalling in primary 
HRS cells with a comprehensive set of TF revealed the up-regulation of 12 TF and the 
down-regulation of 47 TF by PI3-K signalling in HRS cells. 
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Figure 5. BATF3 is overexpressed in HRS cells 
A) IHC of normal tonsil. BATF3-positive cells were mainly located outside the GC some of 
which expressed CD20 and CD30 but not BCL6 (arrowed). MZ=mantle zone, 
IF=interfollicular. B) BATF3 expression in CD30-positive HRS (arrowed) C) BATF3 
mRNA and D) protein expression in HL cell lines. T1-T5 are GC B cells isolated from 5 
donors. 
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Figure 6. BATF3 over-expression contributes to the transcriptional programme of HRS cells 
GO analysis of BATF3 targets in L428 cells. Immunoblotting shows knockdown of BATF3 
in L428 cells. 
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Figure 7. BATF3 regulates S1PR1 expression 
Lower levels of S1PR1 protein were observed following BATF3 knockdown in L428 cells 
(p<0.0001) shown here by IF (A) and confirmed by single cell image analysis (B). BATF3 
knockdown also significantly decreased S1PR1 protein in L1236 and KMH2 cells (both 
p<0.0001; not shown). 
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Figure 8. Proposed model for the regulation of BATF3 by S1P signalling in HRS cells 
S1P levels are regulated by SPHK1, which is upregulated in HRS cells and catalyses S1P 
production, and SGPP1, which is down-regulated in HRS cells and degrades S1P. S1P acts 
on the S1P receptor, S1PR1 and in the absence of S1PR2 this drives PI3-K/Akt signalling 
pathway leading to increased BATF3 expression and downstream aberrant transcription. 
S1PR1 expression is increased by BATF3 leading to a feed-forward loop to sustain S1P 
signalling and constitutive BATF3 transcription. 
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